Concomitant discontinuation of adjuvant hormone therapy and cardiovascular therapy among patients with breast cancer

A large proportion of patients with breast cancer concomitantly use adjuvant hormone therapy and cardiovascular therapy. A population-based cohort study of 5493 breast cancer patients in Stockholm (Sweden) found the highest risk of discontinuing cardiovascular therapy at the time when patients discontinued adjuvant hormone therapy. Patients who discontinued adjuvant hormone therapy were at a higher risk of both breast cancer mortality and cardiovascular mortality. The authors conclude that clinicians should switch from single- to multiple-disease focus to prevent discontinuation of therapies for other diseases among patients with breast cancer.